Jubilant: marginal growth in Q2, hope to better in Q4

The performance of Jubilant Life Sciences was hit due to the USDFA letter and Chinese regulatory issues in the 2nd quarterly results of the current financial year

jubl-365-274x186

The company expects to deliver a stable performance in its business from Q4 FY 2015

The financial results for the quarter ended September 30th were approved by the Board of Jubilant Life Sciences on October 28, 2014. Commenting on the company's performance, Mr Shyam S Bhartia, chairman and managing director and Mr Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences mentioned, "The company's performance in the quarter was affected mainly due to the continued impact of USFDA Warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in Advanced Intermediates business. Our Radiopharmaceuticals business has started to show the benefits of our strategic initiatives."

In Q2, FY2015, income from operations of the pharmaceuticals segment stood at Rs 614 Crore, contributing 45 percent to the revenue mix. The segment EBITDA stood at Rs 69 Crore, with EBITDA margins at 11.3 percent. Excluding one-time expenses of Rs 35 Crore, the margins for the segment stood at 17 percent. For H1 FY2015, Income from Operations stood at Rs 1,218 Crore, contributing 43 percent to the overall revenue mix. The segment EBITDA stood at Rs 105 crore, with EBITDA margins at 8.6 percent. Excluding one-time expenses of Rs 45 Crore, the margins for the segment stood at 12.3 percent.

Operations form the life science ingredients segment was at Rs 757 Crore, up 2 percent YoY and contributing 55 percent to the revenue mix. The segment EBITDA stood at Rs 62 Crore, with EBITDA margins at 8.2 percent. In H1 FY2015, Income from Operations of the segment was at Rs 1,626 crore, up 12 percent YoY and contributing 57 percent to the revenue mix. The segment EBITDA stood at Rs 195 crore, with EBITDA margins at 12 percent.

From the global prespective, the Q2 FY2015, revenues from North America stood at Rs 513 crore, contributing 37 percent to the overall revenues. Revenues from Europe and Japan stood at Rs 277 crore, contributing 20 percent to the revenue mix. Domestic revenues grew 14 percent YoY at Rs 416 crore and thus contributing 30 percent to the mix. Revenues in ROW including China stood at Rs 165 crore, thus contributing 12 percent contribution to the mix.

In H1 FY2015, revenues from North America stood at Rs 1,003 crore, contributing 35 percent to the revenue mix. Revenues from Europe and Japan stood at Rs 607 crore, contributing 21 percent to the revenue mix and growing 5 percent YoY. Revenues from ROW including China stood at Rs 396 crore, contributing 14 percent to the revenue mix. Domestic revenues stood at Rs 839 crore, up 17 percent YoY and contributing 29 percent to the revenue mix.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X